

Thalidomide (Thalomid®)

Selected References:

- Brooks C, et al. 1977. Linear growth of children with limb deformities following exposure to thalidomide in utero. *Acta Paediatr Scand*, 66:673-675.
- Castilla E, et al. 1996. Thalidomide, a current teratogen in South America. *Teratology*, 54:273-277.
- Gao S, et al. 2020. Recent advances in the molecular mechanism of thalidomide teratogenicity. *Biomed Pharmacother*, 127:110114.
- Guo L, et al. 2023. Inflammatory bowel disease can reduce ovarian reserve function in women: a systematic review and meta-analysis. *Medicine (Baltimore)*, 102(11):e33113.
- Gollop T, et al. 1987. Prenatal diagnosis of thalidomide syndrome. *Prenat Diagn*, 7:295-298.
- Ito T, et al. 2020. Molecular mechanisms of thalidomide and its derivatives. *Proc Jpn Acad Ser B Phys Biol Sci*, 96(6):189-203.
- Klein-Weigel PF, Ding-Greiner C. 2025. Cardiovascular manifestations of thalidomide embryopathy. *Vasa*, 54(5):299-304.
- Mahesri M, et al. 2024. Trends in use and evidence of adherence to risk evaluation and mitigation strategy pregnancy testing requirements for thalidomide, lenalidomide, and pomalidomide in the USA, 2000-2020. *Drug Saf*, 47(9):909-919.
- Miller MT, et al. 2009. Thalidomide and misoprostol: ophthalmologic manifestations and associations both expected and unexpected. *Birth Defects Res A Clin Mol Teratol*, 85(8):667-676.
- Peng X, et al. 2017. Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients. *Medicine (Baltimore)*, 96(21):e6540.
- Prescriber Guide to (THALOMID REMS™) Risk Evaluation and Mitigation Strategy (REMS)™ Program. (2014). Retrieved from <https://www.fda.gov/media/79047/download>
- Rodier PM, 2000. The early origins of autism. *Scientific American*, 282:56-63.
- Rodier PM. 2002. Converging evidence for brain stem injury in autism. *Dev Psychopathol*, 14(3):537-557.
- Smithells R. 1992. Recognition of thalidomide defects. *J Med Genet*, 29:716-723.
- Sterling D, et al. 1997. Thalidomide: a surprising recovery. *J Am Pharm Assn*, 3:306-313.
- Stromland K, et al. 1993. Thalidomide embryopathy: revisited 27 years later. *Acta Ophthalmol (Copen)*, 71:238-245.
- Stromland K, et al. 1994 Autism in the thalidomide embryopathy: a population study. *Dev. Med. Child Neurol*, 36:351-356.
- Vargesson N. 2019. The teratogenic effects of thalidomide on limbs. *J Hand Surg Eur Vol*, 44(1):88-95.
- Xiang P, et al. 2023. Clinical characteristics and risk factors of ovarian reserve decreases in women with Crohn's disease: a case-control study. *J Ovarian Res*, 16(1):34.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, November 1, 2025.

Thalidomide (Thalomid®)

Selected References:

- Bateman BT, et al. 2015. Statins and congenital malformations: cohort study. *BMJ*,350:h1035.
- Boyle AK, et al. 2019. Repurposing simvastatin as a therapy for preterm labor: evidence from preclinical models. *FASEB J*, 33:2743-2758.
- Chang J, et al. 2021. Perinatal outcomes after statin exposure during pregnancy. *JAMA Netw Open*, 4(12):e2141321.
- Cleary KL, et al. 2014. Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. *Semin Perinatol*, 38(8):523-527.
- Constantine MM, Cleary K. 2013. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. *Obstet Gynecol*, 121(2 Pt 1):349-353.
- Döbert M, et al. 2021. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. *Circulation*, 144(9):670-679.
- Hirsch A, et al. 2022. The effect of statins exposure during pregnancy on congenital anomalies and spontaneous abortions: A systematic review and meta-analysis. *Front Pharmacol*, 13.
- Jay RH, et al. 1991. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. *Br J Clin Pharmacol*, 32(4):417-422.
- Kane AD, et al. 2022. Combined statin and glucocorticoid therapy for the safer treatment of preterm birth. *Hypertension*, 80(4).
- Kay HY, et al. 2025. Pregnancy and neonatal outcomes after fetal exposure to statins among women with dyslipidemia: a nationwide cohort. *Eur J Pediatr*, 184(6):340.
- Kazmin A, et al. 2007. Risk of statin use during pregnancy: a systematic review. *J Obstet Gynaecol Can*, 29(11):906.
- Kusters DM, et al. 2012. Statin use during pregnancy: a systematic review and meta-analysis. *Expert Rev Cardiovasc Ther*, 10(3):363-378.
- Maierean SM, et al. 2018. The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. *Expert Opin Investig Drugs*, 27(5):427-435.
- McElhatton P. 2005. Preliminary data on exposure to statins during pregnancy. *Reprod Toxicol*, 20:471-472.
- Morton S, Thangaratinam S. 2013. Statins in pregnancy. *Curr Opin Obstet Gynecol*, 25(6):433-440.
- Mudd LM, et al. 2012. Maternal lipids at mid-pregnancy and the risk of preterm delivery. *Acta Obstet Gynecol Scand*, 91(6):726-735.
- Ofori B, et al. 2007. Risk of congenital anomalies in pregnant users of statin drugs. *Br J Clin Pharmacol*, 64(4):496-509.
- Omolaoye TS, et al. 2022. Statins and Male Fertility: Is There a Cause for Concern? *Toxics*, 10(627):1-19.
- Raham DF, et al. 2021. Management of familial hypercholesterolemia in pregnancy. *Curr Opin Lipidol*,

32(6):370-377.

- Svendsen K, et al. 2025. Risk of adverse pregnancy outcomes and impact of statin use in pregnant women with familial hypercholesterolemia. *Atherosclerosis*, 408:120442.
- Taguchi N, et al. 2008. Prenatal exposure to HMG CoA reductase inhibitors: effects on fetal and neonatal outcomes. *Reprod Toxicol*, 26(2):175-177.
- U.S. Food and Drug Administration. 2021. Statins: drug safety communication – FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy. Posted July 20, 2021. Available at URL: <https://www.fda.gov/safety/medical-product-safety-information/statins-drug-safety-communication-fda-requests-removal-strongest-warning-against-using-cholesterol>.
- Vahedian-Azimi A, et al. 2021. Effects of statins on preeclampsia: a systematic review. *Pregnancy Hypertens*, 23:123-130.
- Vahedian-Azimi A, et al. 2021. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. *Atherosclerosis*, 336:1-11.
- Vahedian-Azimi A, et al. 2021. Fetal toxicity associated with statins: a systematic review and meta-analysis. *Atherosclerosis*, 327:59-67.
- Winterfeld U, et al. 2013. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. *BJOG*, 120(4):463-471.
- Wolfgang P, et al. 2004. Pregnancy outcome after medication with HMG-CoA reductase inhibitors in the first trimester. *Reprod Toxicol*, 19:254-255.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, November 1, 2025.

Thalidomide (Thalomid®)

Selected References:

- Beeder LA, et al. 2010. Effect of antidepressant medications on semen parameters and male

fertility. *International Journal of Urology* 27.1: 39-46.

- Dao K, et al. 2023. Reproductive safety of trazodone after maternal exposure in early pregnancy: a comparative ENTIS cohort study. *Journal of Clinical Psychopharmacology* 43.1: 12.
- Einarson A, et al. 2003. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. *Can J Psychiatry* 48(2):106-110.
- Einarson A, et al. 2009. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. *Can J Psychiatry* 54(4):242-246.
- Glasgow-Osment B, et al. 2025. The effects of trazodone exposure during pregnancy on fetal outcomes: a systematic review. *Eur J Clin Pharmacol* 81: 1401-1408.
- Khazaie H, et al. 2013. Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. *Psychiatry Res.* 210(3):901-5.
- McElhatton PR, et al. 1996. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). *Reprod Toxicol* 10:285-94.
- Misri S and Sivertz K. 1991. Tricyclic drugs in pregnancy and lactation: a preliminary report. *Int J Psychiatry Med* 21:157-171.
- Rivett KF and Barcelona PS. 1974. Toxicology of trazodone. *Mod Probl Pharmacopsychiatry* 9:76-86.
- Rosa F. 1994. Medicaid antidepressant pregnancy exposure outcomes. *Reprod Toxicol* 8(5):444-445.
- Verbeeck RK, et al. 1986. Excretion of trazodone in breast milk. *Br J Clin Pharmacol* 22(3):367-370.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, November 1, 2025.

Thalidomide (Thalomid®)

Selected References:

- Bokun V, et al. 2019. Respiratory Syncytial Virus Exhibits Differential Tropism for Distinct Human Placental Cell Types with Hofbauer Cells Acting as a Permissive Reservoir for Infection. *PLoS One*; 14(12):e0225767.

- Centers for Disease Control and Prevention (CDC). 08/2023. Respiratory Syncytial Virus Infection (RSV) web page: <https://www.cdc.gov/rsv/index.html> [Accessed 10/2025].
- Centers for Disease Control and Prevention (CDC). 08/2024. RSV Vaccine Guidance for Pregnant Women. <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html>. [Accessed 10/2025].
- Chu HY, et al. 2016. Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy. *PLoS One*. 2016 Mar 31;11(3):e0152015.
- Chiba Y, et al. 1987. Effect of breast feeding on responses of systemic interferon and virus-specific lymphocyte transformation in infants with respiratory syncytial virus infection. *J Med Virol*; 21(1):7-14.
- Downham MA, et al. 1976. Breast-feeding protects against respiratory syncytial virus infections. *Br Med J*; 2:274-6.
- Ferolla FM, et al. 2013. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. *Am J Respir Crit Care Med*; 187(9):983-90.
- Fonceca AM, et al. 2017. Infective Respiratory Syncytial Virus is Present in Human Cord Blood Samples and Most Prevalent During Winter Months. *PloS One*; 12(4):e0173738.
- Galanti M, et al. 2019. Rates of asymptomatic respiratory virus infection across age groups. *Epidemiol Infect*; 147:e176.
- Hause A, et al. 2021. Adverse Outcomes in Pregnant Women Hospitalized with Respiratory Syncytial Virus Infection: A Case Series, *Clinical Infectious Diseases*; 72(1):138-140.
- Irvine LM, et al. 1990. Elevated viral antibody titres in spontaneous abortion. *FEMS Microbiol Immunol*; 2(1):23-7.
- Kenmoe S, et al; PROMISE Investigators. 2024. Burden of Respiratory Syncytial Virus-Associated Acute Respiratory Infections During Pregnancy. *The Journal of Infectious Diseases* 229(Suppl 1): S51-S60.
- Manti S, et al. 2017. Detection of Respiratory Syncytial Virus (RSV) at Birth in a Newborn with Respiratory Distress. *Pediatr Pulmonol*; 52(10):e81-4.
- Manti S, et al. 2020. Respiratory syncytial virus seropositivity at birth is associated with adverse neonatal respiratory outcomes. *Pediatr Pulmonol*; 55(11):3074-3079.
- Mineva G & Philip R. 2022. Impact of Breastfeeding on the Incidence and Severity of RSV Bronchiolitis in Infants: Systematic Review. *Pediatrics*; 149 (1 Meeting Abstracts): 280.
- Nandapalan N, et al. 1987. Mammary immunity of mothers of infants with respiratory syncytial virus infection. *J Med Virol*; 22:277-87.
- Okamoto Y, et al. 1989. Effect of breast feeding on the development of anti-idiotypic antibody response to F glycoprotein of respiratory syncytial virus in infant mice after post-partum maternal immunization. *J Immunol*; 142:2507-12.
- Patel SM, et al. 2019. Placental transfer of respiratory syncytial virus antibody among HIV-exposed, uninfected infants. *Journal of the Pediatric Infectious Diseases Society*. *Pediatric Infect Dis Soc*. 2020 Jul 13;9(3):349-356.
- Piedimonte G, et al. 2013. Vertical transmission of respiratory syncytial virus modulates pre- and postnatal innervation and reactivity of rat airways. *PLoS One*; 8(4):e61309.
- Regan AK, et al. 2018. Respiratory Syncytial Virus Hospitalization During Pregnancy in 4 High-Income Countries, 2010-2016. *Clin Infect Dis*. 67(12):1915-8.
- Riccò M, et al. 2022. Respiratory Syncytial Virus in Pregnant Women: Systematic Review and Meta-Analysis. *Women*; 2(2):147-160.
- Scott R, et al. 1985. Cellular reactivity to respiratory syncytial virus in human colostrum and breast milk. *J Med Virol*; 17(1):83-93.
- Weinberg A, et al. 2018. Factors associated with lower respiratory tract infections in HIV-exposed uninfected infants. *AIDS Research and Human Retroviruses*. 34(6):527-535.
- Wheeler SM, et al. 2015. Maternal Effects of Respiratory Syncytial Virus Infection during Pregnancy. *Emerg Infect Dis*; 21(11):1951-1955.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, November 1, 2025.

Thalidomide (Thalomid®)

Selected References:

- AAP Committee on Drugs. 2001. The transfer of drugs and other chemicals into human milk. *Pediatrics* 108:776-789.
- Acar S, et al. 2019. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis. *Reprod Toxicol*, 85:65-74.
- Berkovitch M, et al. 1994. Safety of the new quinolones in pregnancy. *Obstet Gynecol*, 84(4):535-538.
- Boissiere-O'Neill T, et al. 2025. Exposure to Systemic Antimicrobials During Pregnancy and Risk of Miscarriage: A Population-Based Registry Study. *BJOG*.
- Bomford JAL, et al. 1993. Ciprofloxacin use during pregnancy. *Drugs*, 45(S3): 461-462.
- Cavusoglu I, et al. 2016. Evaluation of teratogenic effects of ciprofloxacin in pregnant women exposed due to urinary tract infections (abstract). *Reprod Toxicol*, 60:178.
- Cover DL, Mueller BA. 1990. Ciprofloxacin penetration into human breast milk: a case report. *DICP*, 24:703-704.
- Damkier P, et al. 2019. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. *Am J Obstet Gynecol*; 221(6):648.e1-648.e15.
- Gardner D, et al. 1992. Simultaneous concentrations of ciprofloxacin in breast milk and in serum in mother and breast-fed infant. *Clin Pharm*, 11:352-354.
- Kabeya CM, et al. 1995. Ciprofloxacin for multiresistant enteric fever in pregnancy. *The Lancet*, 346:307-308.
- Leung D, et al. 1995. Treatment of typhoid in pregnancy. *The Lancet*, 346:648.
- Loebstein R, et al. 1998. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrob Agents Chemother*, 42(6):1336-1339.

- Meaney-Delman D, et al. 2013 Prophylaxis and treatment of anthrax in pregnant women. *Obstet Gynecol*, 122(4):885-900.
- Muanda FT, et al. 2017. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population-based cohort study. *Br J Clin Pharmacol*; 83:2557-2571.
- Nahum G, et al. 2006. Antibiotic use in pregnancy and lactation. *Obstet Gynecol*, 107(5):1120-1138.
- Noergaard M, et al. 2022. Ciprofloxacin exposure and adverse pregnancy outcomes: A Danish nationwide cohort study. *BJOG*, 129(9):1503-1511.
- Padberg S, et al. 2014. Observational cohort study of pregnancy outcomes after first-trimester exposure to fluoroquinolones. *Antimicrob Agents Chemother*, 58(8):4392-4398.
- Schaefer C, et al. 1996. Pregnancy outcome after prenatal quinolone exposure: evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). *Eur J Obstet Gynecol*, 69:83-89.
- Schluter G. 1989. Ciprofloxacin: toxicologic evaluation of additional safety data. *The Am J Med*, 87(5A):S37-S39.
- Van Wattum JJ, et al. 2019. Antibiotics and lactation: An overview of relative infant doses and a systematic assessment of clinical studies. *Basic Clin Pharmacol Toxicol*, 124(1):5-17.
- Xiang DC, et al. 2024. Pregnancy-related adverse events and congenital disorders associated with fluoroquinolones: A real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). *Heliyon*. 10(18):e37547.
- Xiong W, et al. 2024. Association between maternal antibiotic exposure and emotional and behavioural problems in children at four years of age: A biomonitoring-based prospective study. *Ecotoxicol Environ Saf*. 284:116949.
- Yefet E, et al. 2018. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, November 1, 2025.